Developing novel medicines targeting ferroptosis/ oxidized lipid

FELIQS【fíːlɪks】 is a preclinical-stage start-up company established based on the robust science from molecular pathobiology, department of pharmaceutical science, Kyushu university.

Ferroptosis is a new type of cell death reported in 2012(Cell. 2012 May 25;149(5):1060-72.), and it is caused by the accumulation of oxidized lipids. In recent years, it has been reported to be associated with many diseases such as cancer, ischemia-reperfusion injury, and neurodegenerative diseases, and is being investigated as a new drug target. We have established a unique drug discovery platform targeting ferrotosis, and are now conducting preclinical research toward the clinical trial to create new medicine for unmet medical needs in ophthalmology space.